Karen Smith, M.D., Ph.D.

Chief Medical Officer

Dr. Karen Smith has served as Quince Therapeutics’ Chief Medical Officer since May 2022. To this role, she brings a breadth of experience as a biotech and pharmaceutical executive, board director, and clinical and scientific advisor that spans more than 100 clinical trials and 20-plus regulatory approvals in multiple jurisdictions, including FDA (USA), EMA (Europe), TGA (Australia), ANVISA (Brazil), and PMDA (Japan). Dr. Smith has led product launches across diverse therapeutic areas, including oncology (Herceptin, Vyxeos), rare disease (Defitelio), cardiology (Irbesartan), dermatology (Voluma, Botox, Aczone), neuroscience (Abilify, Solriamfetol), and anti-infectives (Teflaro). In addition to growth and creation of R&D pipelines, her successful record of business development includes acquisitions, divestitures, and partnership deals. Dr. Smith has held various President, Chief Executive Officer, and Chief Medical Officer roles over the past 20 years, building companies from the ground up while advocating for women in science and diversity in the boardroom. Earlier in her career, she held senior leadership roles at Allergan, AstraZeneca, and Bristol Myers Squibb before transitioning to executive roles in several biotech and startup companies. Dr. Smith currently serves on the boards of Antares Pharma (ATRS), Sangamo Tx (SGMO), and Capstan Tx. Previously, she served on the board of Forward Pharma A/S (FWD), Sucampo (SCMP), and Acceleron (XLRN), each with an acquisition exit. Dr. Smith holds several degrees, including an M.D. from the University of Warwick, a Ph.D. in Oncology from the University of California, Los Angeles and The University of Western Australia, a M.B.A. from the University of New England, and an LL.M. (Masters in Law) from the University of Salford.

View Our Leadership